Metabolic & Cardiometabolic
beta-glucan decreases LDL cholesterol
In plain terms: Does oat fibre lower bad cholesterol?
Strong support Metabolic & Cardiometabolic 💰 Industry COI noted
Part of: 🧪 beta-glucan
RefutedContestedStrong support
consensus score 0.96
Yes — oat and barley beta-glucan modestly lowers bad cholesterol at about 3 grams a day.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
12 support 0 contradict 0 tested null 2 mixed · 14 sources, 11 independent groups
What the evidence shows
Oat/barley beta-glucan lowers LDL ~0.25-0.27 mmol/L and non-HDL at >=3 g/day — high-grade, non-contested. ApoB is NOT consistently lowered: the barley MA (Ho 2016) found "no significant changes to apoB" (corrected reread #322; the oat MA found a small ApoB effect). Note the two anchor MAs are the same Toronto lab, grouped accordingly.
The evidence (17)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Zheng R et al] # corrected 2026-08-17 from PubMed; was [2026 2026 · Food Funct. 2026 Jan 12;17(1):70-88 | meta-analysis | supports | moderate | Meta-analysis of 49 studies / 3854 adults with BMI >=25: cereal beta-glucan lowered LDL-C by -0.19 mmol/L (95% CI -0.25 to -0.13, P < 0.001) and total cholesterol by -0.24 mmol/L (-0.31, -0.17), the effect being seen 'particularly with doses ≥3 g day-1 and durations ≥6 weeks' - matching the claim's >=3 g/day scope. Triglycerides, HDL-C, diastolic BP and body weight were all null; BMI was uninterpretable due to publication bias. |
| Ho HV, Sievenpiper JL, Zurbau A, Blanco Mejia S, Jovanovski E, Au-Yeung F, Jenkins AL, Vuksan V 2016 · Eur J Clin Nutr | meta-analysis | supports | high | 14 RCTs, N=615, median 6.5 g/day barley beta-glucan for a median 4 weeks: LDL-C -0.25 mmol/L (95% CI -0.30, -0.20) and non-HDL-C -0.31 mmol/L (95% CI -0.39, -0.23), 'with no significant changes to apoB levels, compared with control diets'; non-HDL-C pool carries considerable unexplained heterogeneity (I2=98%). ⚠️ correction-on-file (Crossref) - kept, corrigendum not retraction |
| Li A, Gao J, Li Y, Qi S, Meng T, Yu S, Zhang Y, He Q 2024 · Food Funct | meta-analysis | supports | moderate | Meta-analysis of 17 RCTs / 1731 dyslipidemic patients: 'oat-based products may result in a large reduction in LDL-C (WMD, -0.24 mmol L-1; 95% CI: -0.33, -0.15) (moderate certainty)' vs placebo/usual diet, and -0.17 mmol/L vs other cereals. Exposure is pooled - 'oat β-glucan-based products to oat bran-based products and wholegrain oat' - with no beta-glucan dose reported, so the effect is not cleanly attributable to beta-glucan alone; included trials had high or some-concerns risk of bias. |
| Amerizadeh A et al] # corrected 2026-08-17 from PubMed; was [2023 2023 · Curr Probl Cardiol | meta-analysis | supports | low | Systematic review WITHOUT meta-analysis (title: 'An Updated Systematic Review'; Europe PMC pubTypeList = ['Systematic Review','Journal Article'], no Meta-Analysis type; abstract-grade read, paper is subscription-locked and not in PMC). 'After searching PubMed, Web of Science, and Google scholar we included 17 studies in our review.' No pooled estimate, no forest plot, no heterogeneity or risk-of-bias statistic, no registration; results are reported as counts of studies. On LDL-C the synthesis is supportive but explicitly derivative: 'Our results similar to other reviews showed that oat reduced the TC, VLDL, and LDL-C more significantly than TG' — no magnitude, no CI, no p. Exposure is oat as a food, not isolated beta-glucan; beta-glucan is named as the active fibre in the premise. LDL-C is also not this paper's stated question — 'We did this review study to find out about the effect of oat on lipid profile especially TG and HDL-C' — and on those focal outcomes the finding is negative: 'Of 17 included studies 6 studies reported reduction of TG level, and only 1 study reported HDL-C improvement followed by oat consumption.' Retained for transparency at zero weight: it restates primaries the vault counts elsewhere. Curr Probl Cardiol 2023;48(7):101153; funding/COI not seen; all authors Isfahan University of Medical Sciences. |
| AbuMweis 2010 · Eur J Clin Nutr | meta-analysis | supports | high | Meta-analysis of 11 RCTs (1989-2008, random-effects): barley and barley-isolated beta-glucan lowered LDL cholesterol by 0.27 mmol/l (95% CI -0.34 to -0.20, P<0.00001) and total cholesterol by 0.30 mmol/l (95% CI -0.39 to -0.21, P<0.00001) vs control. The paper explicitly reports NO dose-response: 'The pattern of cholesterol-lowering action of barley in this analysis could not be viewed as a dose-dependent response', and no significant subgroup differences by intervention type or food matrix. |
| Klümpen L et al 2026 · Nat Commun | RCT | mixed | low | Two parallel open-label RCTs (DRKS00022169, n=17/group) in metabolic syndrome. High-dose 2-day oat diet (13.5 g beta-glucan/d) vs equally hypocaloric macronutrient-matched oat-free control cut LDL-C by 16.26 mg/dL [-23.60, -10.32], P adj. 0.011, and TC by 15.61 mg/dL (about -10% and -8%). The six-week moderate arm (3.5 g beta-glucan/d added to habitual diet) left TC and LDL-C 'largely stable' (AUC 0.58, P 0.399) - hence mixed. Lipids were a SECONDARY outcome; the trial was powered only for plasma dihydroferulic acid. Whole oats, not isolated beta-glucan, and the authors attribute much of the effect to microbial phenolic metabolites 'besides the known mechanism of beta-glucan'. Part-funded by the German cereal-milling industry association and an oat-product company. |
| Ho, Sievenpiper, Zurbau, Blanco Mejia, Jovanovski, Au-Yeung, Jenkins, Vuksan 2016 · Br J Nutr | meta-analysis | supports | moderate | Meta-analysis of 58 RCTs (n 3974; 56 trials, n 3745 for LDL-C), median oat beta-glucan dose 3·5 g/d over a median 6 weeks: 'Overall, a significant LDL-cholesterol reduction was observed ... (MD=−0·19 mmol/l; 95 % CI −0·23, −0·14; P<0·00001)', i.e. −4·2 % relative, and 'Systematic removal of individual trials did not alter the results.' Quality tempered high -> moderate on the paper's own disclosures rather than on the result: the trial base is weak ('Very few studies (nine trials, 16 %) were considered to be of higher quality (MQS>=8)'; 'thirty trials (50 %) had high risk of bias ... for blinding of participants and personnel'); heterogeneity is considerable and unexplained (I2=79 %); the funnel plot leans one way ('minor asymmetry ... with tendencies for the publication of small and/or imprecise trials favouring oat β-glucan', Begg's P=0·061); dose itself was inferred, not assayed — 'the β-glucan content of oats was estimated for the majority of trials as it was not routinely analysed and reported'; 34 % of pooled trials were industry-funded and one unpublished in-house dataset was included; and the senior author holds a patent on 'medical use of viscous fibre blend' for blood lipids. The authors' own bottom line: 'Because of considerable unexplained heterogeneity, caution should be taken when interpreting the results.' Note also that the prior extract's health-claim-dose gloss overstates the finding — the >=3·0 vs <3·0 g/d contrast was only 'a trend towards treatment modification by dose (P=0·051)'. Separately, and answering the apoB question against the barley sibling: this oat review DID find apoB lowering — 'a significant lowering of apoB ... (MD=−0·03 g/l; 95 % CI −0·05, −0·02; P<0·0001)' from 17 trials (n 1070), −2·3 % relative, I2=38 %. |
| Okuma T et al 2025 · Foods (MDPI) 2025;14(24):4346 | observational | supports | low | Single-arm, open-label, uncontrolled before-after study (UMIN000031666), n=24 Japanese stage G2-4 CKD outpatients, breakfast replaced by 50 g Calbee Fruits Granola >=5 days/week for 2 months. LDL-C fell 104.6 +/- 25.4 to 98.2 +/- 23.9 mg/dL (p=0.03) and LDL/HDL 2.3 to 2.1 (p<0.01). But the exposure is not beta-glucan: the paper states 'FGR in this study contained 0.75 g of beta-glucan, suggesting that supplementation with water-soluble dietary fibers, including beta-glucan, MAY have contributed' - a quarter of the >=3 g/day the claim is scoped to and the dose the paper's own cited meta-analysis requires ('A meta-analysis showed that consuming 3 g of beta-glucan per day reduces LDL-C levels'). No comparator ('Since FGR contains multiple ingredients, a placebo group was not possible'), no diet records ('Because the participants' dietary habits during the study were unknown, it is unclear whether their diets contributed to the reductions in blood pressure, LDL-C, the LHR, and NAG'), and funded by the product's manufacturer via an endowed Calbee-Juntendo research course with a Calbee R&D author. Off-scope for beta-glucan; it is a whole-food granola result. |
| Whitehead A, Beck EJ, Tosh S, Wolever TMS 2014 · Am J Clin Nutr | meta-analysis | supports | moderate | [FT+supplement verified 2026-08-19] Random-effects meta-analysis of 28 RCTs (18 parallel, 10 crossover; 2-12 wk; 3.0-12.4 g/d oat beta-glucan of MW >=100 kDa vs low-soluble-fibre or insoluble-fibre control): LDL fell 'of -0.25 mmol/L (95% CI: -0.30, -0.20'; P < 0.0001, heterogeneity P = 0.13, I2 = 22%. Total cholesterol fell 'of -0.30 mmol/L (95% CI: -0.35, -0.24'. Direction is solid and agrees with three earlier independent meta-analyses, so the supports stance stands. Quality lowered high -> moderate on bias evidence the paper reports about ITSELF: 'The effect of OBG was significantly less by 0.11 mmol/L' (P = 0.024) ') on LDL cholesterol and 0.13 mmol/L' (P = 0.021) 'on total cholesterol for trials in which blinding of outcome assessors was specifically mentioned relative to the other trials.' All five quality covariates in Supplemental Table 4 (randomisation, blinding of subjects, of caregivers, of outcome assessors, compliance reporting) attenuate the effect in the same direction, and 'As suggested by the meta-regressions on the quality questions, the funnel plots show some association between OBG effect and study quality, with lower study quality being associated with a larger effect.' The corpus is sponsor-curated: 'Supported by DSM Nutritional Products.', 'AW's institution received funding from DSM Nutritional Products for her participation in the study.', and the search deliberately included 'in-house study reports at CreaNutrition AG' - 'CreaNutrition AG is the Switzerland-based international marketing, sales, and research subsidiary of Swedish Oat Fiber AB' - yielding one unpublished, externally unverifiable trial (Donazzolo, n=71). Senior author TMS Wolever's own RCT supplies four of the pooled comparisons. Practical read: the LDL reduction is real, but the blinded-subset estimate is nearer 0.14 than 0.25 mmol/L. Scope note: oat beta-glucan only - barley beta-glucan was not included. No dose-response across 3.0-12.4 g/d (slope 0.0035, P = 0.76), no duration effect across 2-12 wk, and no trial ran beyond 12 wk. |
| Afify MAEA et al 2026 · Nutrients | RCT | supports | low | Open-label randomized crossover, n=60 adolescents with T1D, oat-flake beta-glucan 6 g/day x3mo per period, 2-wk washout, control = ordinary diet with no placebo ('The study was open-label.'). LDL-C fell 70.33 +/- 35.76 -> 54.83 +/- 25.48 mg/dL on beta-glucan vs a rise to 88.07 +/- 22.53 on ordinary diet (both p<0.001); between-arm median percentage change −19.47% (IQR −26.19 to −13.8) vs +5.75% (1.23-17.74), p<0.001. Direction supports the claim and 6 g/day is inside its >=3 g/day scope, but quality is low: Table 2's 'baseline' LDL of 70.33 cannot be reconciled with Table 1's randomized baselines of 102.0 +/- 36.68 (group A) and 91.6 +/- 22.45 (group B), the same single baseline is used for BOTH arms so the control arm's LDL rise is partly post-crossover rebound ('These changes were not sustained after discontinuation of the oat flakes, except for the HDL-C'), and the exposure is whole-food oat flakes with unstandardized meals ('One limitation of the current study is the lack of standardized meals, relying on patients' self-reported intake') alongside concurrent BMI z-score and insulin-dose reductions. |
| Shi S et al 2025 · Int J Biol Macromol | animal | mixed | low | Diet-induced hypercholesterolemic mice, 12wk, arms = model / atorvastatin 5 mg/kg/day / L. paracasei K56 5 x 10^9 CFU/kg / oat beta-glucan (OBG) 1 g/kg/day / OBG+K56. The only LDL-C result reported is for the COMBINATION: it reduced 'low-density lipoprotein cholesterol (LDL-C) by 37.47 +/- 6.55 % (vs model group)'. No OBG-alone vs model LDL-C figure is given; the sole OBG-arm contrast is on total cholesterol and runs against monotherapy - the combination gave '24.37 +/- 9.18 % (vs OBG group) ... greater TC reduction' - and the paper's premise is that 'current evidence suggests limited efficacy when used alone'. Abstract-only (full text subscription-gated), n per arm not reported, tested probiotic is a commercial dairy strain with four co-authors at the dairy technology centre behind it. Beta-glucan's independent LDL-C effect is therefore cannot-tell from available text. |
| Tiwari 2011 · Nutrition | meta-analysis | supports | moderate | Meta-analysis of 30 articles / 126 clinical studies: 'low-density lipoprotein (-0.66 mmol/L, 95% CI -0.96 to -0.36)', significant in both random- and fixed-effect models, with '3-g/d dose of oat or barley beta-glucan was sufficient to decrease TC'. Downgraded to moderate quality: the same Results sentence bundles TGL/TAG (-0.04 mmol/L, 95% CI -0.15 to 0.07) into 'a significant inverse relation' although that interval crosses zero, the pooled units are called 'epidemiologic studies' in the Objective but 'clinical studies' in the Methods, and the -0.66 mmol/L LDL effect is ~2.5x the replicated consensus estimate. The prior extracted also claimed beta-glucan 'improved glucose'; the paper's own conclusion is that 'the effect on BGL is still inconclusive, with high heterogeneity'. |
| Ma Q et al 2026 · Asia Pac J Clin Nutr | RCT | supports | low | Acute single-meal randomized crossover, n=20 healthy subjects aged 19-24, 100 g portions of steamed bun (refined control), maize, buckwheat and oat pancake, blood at 0/0.5/1/2/3 h with a one-week washout. The finding: 'However, compared with the control group, the concentrations of serum TC and LDL-C in the oat pancake group were significantly reduced (p <0.05), which may be attributed to the presence of beta-glucan and higher dietary fiber in oat pancakes.' OFF-SCOPE on two independent grounds, both readable in that one sentence. (1) SUBJECT: the tested exposure is a whole oat pancake. Beta-glucan was never quantified, isolated or dose-controlled, and no beta-glucan contrast exists in the design — the attribution is the authors' conjecture ('may be attributed'), offered alongside 'higher dietary fiber' as a rival explanation they did not separate. (2) OUTCOME: this is a 3-hour postprandial LDL-C excursion after a single meal, whereas the claim scopes sustained intake at >=3 g/day lowering fasting LDL by ~0.25-0.27 mmol/L; no mechanism moves circulating LDL-C in three hours, and with seven analytes across three test foods and five timepoints and no stated multiplicity correction the result is as consistent with chance as with an effect. Retained on the claim for transparency at zero weight (CONVENTIONS 5). Abstract-only: the Results section was not obtainable. |
| Xu 2021 · Br J Nutr | meta-analysis | supports | high | MA of 21 RCTs: >=3 g/d beta-glucan >=3wk lowered LDL-C 0.26 mmol/L |
| Llanaj E et al] # corrected 2026-08-17 from PubMed; was [2022 2022 · Eur J Nutr | meta-analysis | supports | low | Systematic review of 74 RCTs (4,937 adults, mostly hypercholesterolaemic/obese), 59 pooled in three separate random-effects meta-analyses split by control arm. LDL-C fell in all three: vs no-oat controls − 0.29 mmol/L (− 0.37; − 0.20), 12 RCTs n=589, I²=72.6%; oat + dietary restriction vs restriction alone − 0.26 mmol/L (− 0.38; − 0.14), 9 RCTs n=804, I²=94.1%; vs heterogeneous controls (wheat/rice/eggs) − 0.163 mmol/L (− 0.216; − 0.109), 26 RCTs n=1,823, I²=95.4%. Leave-one-out robust, no publication bias. Direction supports the claim and the magnitude matches the vault's 0.25-0.27 mmol/L figure, but this is oats-as-food, not isolated beta-glucan, and the dose is never resolved: 'Due to the limited number of studies included, we could not stratify the meta-analyses based on intervention type (oat or OβGREs) or on intervention's daily dose' — 60/74 RCTs used oat bran, meal or porridge and only 13 used beta-glucan-containing oat products, so beta-glucan cannot be separated from the whole oat matrix or from displacement of the comparator food. Quality low, not moderate: 'The majority of included RCTs (81.1%) had some concerns for risk of bias' with a further 13.5% at high risk and only 5.4% low; heterogeneity is near-total in two of three pools; and 'This research was supported by Standard Process Inc.', a supplement manufacturer whose two employees co-authored and 'participated data extraction, synthesis and interpretation', with a personal fee to the corresponding author. The abstract is also internally unreliable — it credits the heterogeneous-control comparison with lowering HbA1c, diastolic BP and HDL-C when Tables 3 and 4 place all three in the oat+dietary-restriction pool. |
| de Morais Junior AC et al] # corrected 2026-08-17 from PubMed; was [2023 2023 · Clin Nutr ESPEN | meta-analysis | supports | moderate | SR/MA of 28 blinded placebo-controlled RCTs (1494 subjects, 14-84 d), analysing whole oats and isolated beta-glucan as SEPARATE comparisons. Subject arm: 9 parallel-arm isolated-beta-glucan RCTs lowered LDL, SMD -0.58 (95%CI -0.85 to -0.32, p < 0.0001), robust to leave-one-out but heterogeneous (I2 = 68%); the 3-study crossover arm was null for LDL, SMD -0.74 (95%CI -1.55 to 0.07, p = 0.07, I2 = 88%). Whole oats also lowered LDL (parallel -0.51; crossover -0.38). HDL unchanged by either (beta-glucan -0.04, 95%CI -0.18 to 0.10). Caveats: pooled in SMD not mmol/L; beta-glucan dose 1.2-11.2 g/day with no dose floor, so it does not speak to the claim's >=3 g/day scope; 19/28 primary trials rated high risk of bias under RoB 2; no trial compared oats against isolated beta-glucan directly, so 'beta-glucan is the active fraction' is an indirect inference, not a demonstration. No industry funding. |
| Yu J., Xia J., Yang C., Pan D., Xu D., Sun G., Xia H. 2022 · Nutrients | meta-analysis | supports | moderate | MA of 13 RCTs (14 effect sizes), 927 hypercholesterolemic adults aged 38-76, oat beta-glucan 1.5-6 g/d for 3-8 weeks vs beta-glucan-free control: LDL-c WMD -0.27 mmol/L (95% CI -0.35 to -0.20; p=0.000) with I2=83.3% (p=0.000) that subgroup analysis and meta-regression failed to explain; TC -0.24 mmol/L (-0.28 to -0.20; I2=38.9%). Eight of the included trials were individually significant on LDL-c, the rest were not, but the direction holds in every LDL subgroup: mild -0.28 (-0.38, -0.18), moderate -0.22 (-0.24, -0.20), <=3 g/d -0.22 (-0.24, -0.20; I2=0.0%), >3 g/d -0.28 (-0.40, -0.15; I2=87.0%). No publication bias for LDL (Egger p=0.519); Cochrane risk-of-bias applied per trial, with High or Unclear ratings for Onning 1999, Kerckhoffs 2003 and Gulati 2017. Null on TG (-0.04; -0.13 to 0.05; I2=90.3%) and HDL-c (0.00; -0.05 to 0.05; I2=97.7%). No PROSPERO/protocol registration and no GRADE rating anywhere in the text; authors' own limitations: 'we failed to find the precise sources of heterogeneity in TG, HDL-c, and LDL-c via subgroup analysis and meta-regression' and 'this meta-analysis was not persuasive enough given its limited sample size.' Public funding, no declared COI, but the review pools co-author Xu D.'s own 2021 trial. NOT independent of s32378501 (Xu 2021 Br J Nutr MA, this paper's ref [32]): four shared authors and the same Southeast University department. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.